Zc(=o)oy, Wherein Z Is An Acyclic Radical Bonded To The C=o By A Carbon And Y Is An Organic Radical Bonded To The Oxygen By A Carbon Patents (Class 514/546)
  • Patent number: 10251825
    Abstract: A composition comprising a compound having a Formula I: wherein T is derivative of a terpene and R is a derivative of a neurotransmitter amino acid. Pharmaceutical formulations for topical use as insect repellents including the terpenes and terpene esters in form of the pharmaceutically acceptable salt or base are provided. A process for preparing the composition and the formulations are also provided.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: April 9, 2019
    Inventors: Iryna Kravchenko, Mariia Nesterkina, Sergiy Lozovsky
  • Patent number: 10195137
    Abstract: A method comprising topically applying to facial skin a composition comprising an aqueous, alcoholic, or aqueous-alcoholic extract from Nymphoides peltatum.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: February 5, 2019
    Assignee: Mary Kay Inc.
    Inventors: Tiffany Florence, David Gan, Michelle Hines
  • Patent number: 10143697
    Abstract: A pharmaceutical composition comprises a HDAC inhibitor, a pharmaceutically acceptable acid or a salt thereof or a mixture thereof and a steroid or a pharmaceutically acceptable salt thereof as well use of said pharmaceutical composition for the treatment of cancer as a pretreatment prior to other treatments. Said HDAC inhibitor or steroid may alternatively be administrated separately prior to additional treatments.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: December 4, 2018
    Assignee: VALCURIA AB
    Inventors: Kristina Drott, Thomas Relander
  • Patent number: 10130606
    Abstract: Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle are described as retinoid replacement therapies for treating retinal degenerations in humans.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: November 20, 2018
    Assignee: NOVELION THERAPEUTICS INC.
    Inventor: Ronald Erwin Boch
  • Patent number: 10111820
    Abstract: A composition directed to a rinse-off composition for hair frizz reduction comprising from about 0.2% to about 20.0% of a moisture control material or mixture of moisture control materials wherein the moisture control material is selected from one or more of the following: a) wherein R is hydrogen or metal ion, R6 is methyl, ethyl, propyl, alkenyl or phenyl having less than 12 carbon atoms and wherein R7, R8, R9, R10, R11, R12 are hydrogen, methyl, ethyl, propyl, phenyl, hydroxyl, methoxy or ethoxy groups; b) an alcohol wherein R13 is an alkyl, alkenyl, straight or branched carbon chains and; and wherein R14 is hydrogen, hydroxyl, alkyl, methyl, ethyl and propyl wherein the structure of such alcohol contains less than 20 total carbon atoms; c) alcohol comprising an unsaturated double bond in the C2 position.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: October 30, 2018
    Assignee: The Procter and Gamble Company
    Inventors: Jennifer Mary Marsh, Supriya Punyani, MuiSlang Soh, Jiazhen Zhang, Chetan Yagnik, Phan Shean Lim, Brian Xiaoqing Song, Tiffany Tien-Yun Yang
  • Patent number: 10105332
    Abstract: The present disclosure relates to methods and compositions for suppressing the growth of fungus on selected areas of the skin. A composition for suppressing deep seated fungal growth comprising conjugated linoleic acid, Punicic acid, or combination thereof, and niacinamide and L-aspartic acid is provided herein. Methods of making and using the composition are also presently provided.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: October 23, 2018
    Inventor: David Changaris
  • Patent number: 10098864
    Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: October 16, 2018
    Assignees: Enzychem Lifesciences Corporation, Korea Research Institute of Bio Science and Biotechnology
    Inventors: Sei-Ryang Oh, Kyung Seop Ahn, Su Ui Lee, In Sik Shin, Na-Rae Shin, Tae-Suk Lee, JongKoo Kang, Young-Sik Jung, Yong-Hae Han, Ki Young Sohn
  • Patent number: 10058521
    Abstract: Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: August 28, 2018
    Assignee: MATINAS BIOPHARMA INC.
    Inventors: George Bobotas, Abdel Aziz Fawzy
  • Patent number: 10052300
    Abstract: The present disclosure relates to methods and compositions for suppressing the growth of fungus on selected areas of the skin. A composition for suppressing deep seated fungal growth comprising conjugated linoleic acid, Punicic acid, or combination thereof, and niacinamide and L-aspartic acid is provided herein. Methods of making and using the composition are also presently provided.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: August 21, 2018
    Inventor: David Changaris
  • Patent number: 10045531
    Abstract: The present invention relates to the use of one or more fatty acid esters, particularly 3-methylbutyl dodecanoate, or a mixture of fatty acid esters as insecticide and/or arachnicide and moreover relates to insecticide and/or arachnicide compositions containing same. The invention also relates to a method for controlling insects and/or arachnids.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: August 14, 2018
    Assignee: OLEON NV
    Inventors: Pierre Ravier, Matthieu Chatillon, Sebastien Barreau
  • Patent number: 9994511
    Abstract: The present invention is directed to pharmaceutical compositions comprising compounds found in Harderian gland secretions, a method of treating dry eye in a human comprising ophthalmically administering an effective amount of a compound, e.g. a lipid compound, found in Harderian gland secretions, pharmaceutical compositions comprising said lipid compounds, as identified by characteristic chemical data and mass spectra of said lipid compounds, said lipid compound in essentially pure form, and an ophthalmic vehicle comprising a therapeutic agent and a compound present in the secretions of the Harderian gland, e.g. a lipid compound, found in the secretions of the Harderian gland, e.g. a rabbit Harderian gland.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: June 12, 2018
    Assignee: RestorTears, LLC
    Inventors: Daniel M. Albert, Arthur S. Polans
  • Patent number: 9884032
    Abstract: The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: February 6, 2018
    Assignee: PROPONENT BIOTECH GMBH
    Inventor: Bettina Ernst
  • Patent number: 9763908
    Abstract: The present invention relates to a pharmaceutical composition, functional health food composition, quasi-drug composition, and cosmetic composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing, treating or improving atopic dermatitis. The monoacetyldiacylglycerol compound of the present invention has an excellent effect of suppression of IL-4 and IgE secretion, thereby overcoming side effects of an atopic dermatitis treatment agent currently in use, having no toxicity, and exhibiting an excellent treatment effect, and thus can be useful as a composition for preventing, treating, and ameliorating atopic dermatitis.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: September 19, 2017
    Assignees: ENZYCHEM LIFESCIENCES CORPORATION, KOREA RESEARCH INSTITUTE OF BIONSCIENCE AND BIOTECHNOLOGY
    Inventors: Jae Wha Kim, Sei-Ryang Oh, Kyung Seop Ahn, Ho Bum Kang, Jae Mine Yoo, Tae-Suk Lee, JongKoo Kang, Hye Kyung Kim, Jin Soo Yook, Yong-Hae Han, Ki Young Sohn
  • Patent number: 9707173
    Abstract: The present invention is directed to the provision of a pharmaceutical suspension. The suspension includes high molecular weight polyethylene glycol as a suspending agent. The suspension also typically includes an antimicrobial agent (e.g., polymeric quaternary ammonium compound), an antimicrobial system (e.g., borate/polyol complex system) or both. The suspension has been found particularly useful as an ophthalmic suspension, but can be used in other instances as well.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: July 18, 2017
    Assignee: Alcon Research, LTD.
    Inventor: Bhagwati P. Kabra
  • Patent number: 9693557
    Abstract: Compositions (feeding deterrent/repellent for Halyomorpha halys) containing at least two compounds selected from tridecane, E-2-decenal, isolongifolanone, isolongifolenone, and at least one isolongifolenone analog having the following formula: wherein R1 is hydrogen, an oxygen, a C1-10 alcohol, aldehyde, alkyl, ether, or esters of said alcohol with a C1-10 saturated or unsaturated, straight or branched acid and R2 is hydrogen, an oxygen, a C1-10 alcohol, aldehyde, alkyl, ether, or esters of said alcohol with a C1-10 saturated or unsaturated, straight or branched acid; optionally there is a double bond between carbons 5 and 6 and R2 is hydrogen; and optionally a carrier or carrier material. Also methods for deterring feeding/repelling Halyomorpha halys involving treating an object or area with a Halyomorpha halys deterring feeding/repelling effective amount of at least one compound selected from the above compounds.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: July 4, 2017
    Assignee: The United States of America, as Represented by the Secretary of Agriculture
    Inventors: Aijun Zhang, Christina Harris, Tracy C. Leskey
  • Patent number: 9668951
    Abstract: Biodegradable pharmaceutical compositions comprising 1,3-propanediol and its esters are provided. The 1,3-propanediol and its esters in the pharmaceutical composition are biologically derived, and as such, the pharmaceutical compositions exhibit a low anthropogenic CO2 emission profile.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: June 6, 2017
    Assignee: DuPont Tate & Lyle Bio Products Company, LLC
    Inventors: Robert Miller, Joseph Desalvo, Gyorgyi Fenyvesi, Melissa Joerger, Raja Hari Poladi, Ann Wehner
  • Patent number: 9668997
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: June 6, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Patent number: 9580386
    Abstract: The invention relates to compounds that have an affinity to the ?-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: February 28, 2017
    Assignee: GRÜNENTHAL
    Inventors: Bert Nolte, Wolfgang Schröder, Klaus Linz, Werner Englberger, Hans Schick, Heinz Graubaum, Birgit Braun, Sigrid Ozegowski, József Bálint, Helmut Sonnenschein
  • Patent number: 9463154
    Abstract: Disclosed is a method of topically applying Myriophyllum spicatum extract to skin, the method comprising topically applying a composition comprising Myriophyllum spicatum extract to skin.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: October 11, 2016
    Assignee: Mary Kay Inc.
    Inventors: Tiffany Florence, David Gan, Michelle Hines
  • Patent number: 9439972
    Abstract: The subject invention is based upon the discovery that an antifungal agent can be delivered through the fingernail or the toenail of an infected human to treat onychomycosis by dissolving or dispersing the antifungal agent in a solvent system which is comprised of a combination of an alkyl lactate and Simmondsia chinesis seed oil. In accordance with this invention the antifungal agent is absorbed by and incorporated into the nail matrix by diffusing through the epithelium of the nail bed to reach the nail bed hyperkeratosis. The antifungal agent additionally penetrates into the ventral surface of the nail plate. The subject invention more specifically discloses an antifungal serum which is comprised of (1) an alkyl lactate, such as isoamyl lactate, (2) Simmondsia chinesis seed oil, and (3) an antifungal agent, such as tolnaftate or undecylenic acid.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: September 13, 2016
    Assignee: Ad Lunam Labs, Inc.
    Inventor: Turner Rockhill
  • Patent number: 9415033
    Abstract: The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: August 16, 2016
    Assignee: PROPONENT BIOTECH GMBH
    Inventor: Bettina Ernst
  • Patent number: 9408801
    Abstract: Disclosed is a topical skin composition and corresponding methods for its use that includes an extract from Bauhinia glauca, an extract from Rhodendron siderophyllum, and an extract from Circidiphyllum japonicum.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: August 9, 2016
    Assignee: Mary Kay Inc.
    Inventors: Tiffany Florence, David Gan, Michelle Hines
  • Patent number: 9375390
    Abstract: Biodegradable agricultural compositions comprising 1,3-propanediol and its esters are provided. The 1,3-propanediol and its esters in the agricultural composition are biologically derived, and as such, the agricultural compositions exhibit a low anthropogenic CO2 emission profile.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: June 28, 2016
    Assignee: DuPont Tate & Lyle Bio Products Company, LLC
    Inventors: Robert Miller, Joseph Desalvo, Gyorgyi Fenyvesi, Raja Hari Poladi, Ann Wehner
  • Patent number: 9345672
    Abstract: The present invention is directed to compositions and methods of delivery of CoQ that is reduced in the presence of lipoic acid and, optionally a fatty acid and/or optionally in a monoterpene. The compositions that include the reduced CoQ can be formulated in soft gel capsules.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: May 24, 2016
    Assignee: Soft Gel Technologies, Inc.
    Inventor: Michael Fantuzzi
  • Patent number: 9334229
    Abstract: Hydroxytyrosol derivative compositions, methods for their manufacture, and their use in personal care products are disclosed. Lipophilic hydroxytyrosol carbonate ester compound can be made by oxidizing a substituted hydroxybenzaldehyde compound with an oxidizing agent such as hydrogen peroxide under mild conditions. The process involves enzymatic esterification of 4-(2-hydroxyethyl)phenol to form the corresponding ester, the introduction of a formyl group ortho to the phenolic hydroxyl group of the ester to form a lipophilic formyltyrosol ester; oxidation of the lipophilic formyltyrosol ester with a peroxide compound to form a lipophilic hydroxytyrosol ester compound; and reaction of lipophilic hydroxytyrosol ester compound with carbonic acid ester derivatives to form a lipophilic hydroxytyrosol carbonic ester compound. These compounds are useful is a wide variety of personal care compositions as anti-aging compounds that are stable against oxidation.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: May 10, 2016
    Assignee: Eastman Chemical Company
    Inventors: Neil Warren Boaz, Robert Joseph Maleski
  • Patent number: 9333167
    Abstract: Disclosed is a method of lightening skin or evening skin tone, the method comprising topically applying to skin in need thereof a composition comprising an extract from Rhododendron moulmainense, wherein topical application of the composition lightens skin or evens skin tone.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: May 10, 2016
    Assignee: Mary Kay Inc.
    Inventors: Tiffany Florence, David Gan, Michelle Hines
  • Patent number: 9320280
    Abstract: Compositions (feeding deterrent/repellent for Halyomorpha halys) containing at least two compounds selected from tridecane, E-2-decenal, isolongifolanone, isolongifolenone, and at least one isolongifolenone analog having the following formula: wherein R1 is hydrogen, an oxygen, a C1-10 alcohol, aldehyde, alkyl, ether, or esters of said alcohol with a C1-10 saturated or unsaturated, straight or branched acid and R2 is hydrogen, an oxygen, a C1-10 alcohol, aldehyde, alkyl, ether, or esters of said alcohol with a C1-10 saturated or unsaturated, straight or branched acid; optionally there is a double bond between carbons 5 and 6 and R2 is hydrogen; and optionally a carrier or carrier material. Also methods for deterring feeding/repelling Halyomorpha halys involving treating an object or area with a Halyomorpha halys deterring feeding/repelling effective amount of at least one compound selected from the above compounds.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: April 26, 2016
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Aijun Zhang, Christina Harris, Tracy C. Leskey
  • Patent number: 9272049
    Abstract: Provided herein are compositions and methods for preventing and treating diseases and risk factors associated with metabolic syndrome by targeting the RGD-binding site of selected intra- and extracellular proteins. Exemplary compositions include RGD-polyphenol conjugates via an ester linkage; polyphenol polymer conjugated to RGD analogs or mimetics; and RGD polymer conjugates linked to polyphenol.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: March 1, 2016
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Maria Alexander-Bridges, Shaker A. Mousa, Paul J. Davis
  • Patent number: 9272982
    Abstract: A process is described for preparing fesoterodine fumarate comprising the salification reaction of fesoterodine with fumaric acid in an organic solvent, preferably a ketone, at a temperature not greater than 45° C. Such process allows obtaining products with high yields and purities, and in particular a product having a content of (2E)-4-[(3-(3-diisopropylamino-1-phenylpropyl)-4-(2-isobutyroyloxyphenyl)methoxy]-4-oxobut-2-enoic acid less than or equal to 0.15% by mole.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: March 1, 2016
    Assignee: CHEMI S.P.A.
    Inventors: Umberto Ciambecchini, Elio Ullucci, Stefano Turchetta, Maurizio Zenoni
  • Patent number: 9254324
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: February 9, 2016
    Assignee: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Patent number: 9138415
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: September 22, 2015
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Patent number: 9132113
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing ThI cytokine expression, and decreasing Th2 cytokine expression. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols or therapeutic agents used to treat opportunistic infections due to HIV in mammalian subjects.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: September 15, 2015
    Assignee: BIOSUCCESS BIOTECH COMPANY
    Inventors: Zheng Tao Han, Richard L. Chang
  • Patent number: 9073833
    Abstract: An oxime-based compound having the following formula (I) or a pharmaceutically acceptable salt thereof: wherein: Y is a carbonyl group or a sulfonyl group; R1 is selected from H, OH, a C1-C4 alkyl group, and a C1-C4 alkoxyl group; R2 is selected from OH, a methoxyl group, —OR4OH, and —OR4NH2, R4 being a C1-C3 alkyl group; and R3 is H or a pivaloyloxybenzenesulfonyl group.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: July 7, 2015
    Assignee: Chang Gung University
    Inventors: Pei-Wen Hsieh, Tsong-Long Hwang, Wen-Hui Wang, Ting-Yi Wang
  • Patent number: 9060983
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: June 23, 2015
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Patent number: 9060982
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: June 23, 2015
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Publication number: 20150141509
    Abstract: The present invention is directed to pharmaceutical compositions comprising compounds found in Harderian gland secretions, a method of treating dry eye in a human comprising ophthalmically administering an effective amount of a compound, e.g. a lipid compound, found in Harderian gland secretions, pharmaceutical compositions comprising said lipid compounds, as identified by characteristic chemical data and mass spectra of said lipid compounds, said lipid compound in essentially pure form, and an ophthalmic vehicle comprising a therapeutic agent and a compound present in the secretions of the Harderian gland, e.g. a lipid compound, found in the secretions of the Harderian gland, e.g. a rabbit Harderian gland.
    Type: Application
    Filed: October 24, 2014
    Publication date: May 21, 2015
    Inventors: Daniel M. Albert, Arthur S. Polans
  • Patent number: 9034918
    Abstract: The present invention relates to a composition, in particular an antibacterial drug, including trans-cinnamaldehyde, a pharmaceutical composition including trans-cinnamaldehyde for treatment or prevention, in particular, of a nosocomial infection, specifically caused by a bacteria resistant to anti-bacterial drugs, the use of trans-cinnamaldehyde as an anti-bacterial agent and a method for preparing a surface including the application of a composition according to the invention.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: May 19, 2015
    Assignee: SEPTEOS
    Inventor: Nicolas Tesse
  • Publication number: 20150133549
    Abstract: Methods of retarding formation of a lipofuscin pigment in the retina and of treating or ameliorating the effects of a disease characterized by an accumulation of a lipofuscin pigment in a retina are provided. These methods include the step of administering to a patient in need thereof a substituted C20-retinoid in an amount sufficient to reduce accumulation of a lipofuscin pigment in the retina. Further provided are methods of retarding formation of A2E and/or ATR-dimer by replacing an all-trans-retinal (ATR) substrate with a C20-D3-retinal substrate under conditions sufficient to impede the formation of A2E. Compositions for retarding formation of a lipofuscin pigment in the retina containing a substituted C20-retinoid and a pharmaceutically acceptable carrier are also provided.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 14, 2015
    Inventor: Ilyas Washington
  • Publication number: 20150133405
    Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 14, 2015
    Inventors: Marc F. Pelletier, George William Farr, Paul Robert Mcguirk, Christopher H. Hall, Walter F. Boron
  • Publication number: 20150133408
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia, restless leg syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of motor neurone disease, diabetic neuropathy, postherpetic neuralgia, acute opioid withdrawal management, obsessive-compulsive disorder, premature ejaculation, PTSD, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, bipolar depression, depression, stress, cancer pain and lower back pain.
    Type: Application
    Filed: February 16, 2013
    Publication date: May 14, 2015
    Inventor: Mahesh KANDULA
  • Publication number: 20150133548
    Abstract: Disclosed is the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for use in a method of treating a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. 9. Also disclosed is the use of the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for the manufacture of a medicament for use in the treatment of a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. In certain embodiments, the combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine are orally administered via a nutritional composition.
    Type: Application
    Filed: January 10, 2013
    Publication date: May 14, 2015
    Applicant: ABBOTT LABORATORIES
    Inventors: Jeffrey L. Nelson, Anne C. Voss, Maria G. Baggs, Charles L. Paule, Refaat A. Hegazi, Fabrizis Suarez, Gary Fanjiang
  • Publication number: 20150118165
    Abstract: The present invention relates to the use of at least one cyclohexanol ether derivative of the formula I as antimicrobial active compound or as anti-acne, antidandruff, deodorant or antiperspirant active compound, to preparations comprising these compounds, and to specific cyclohexanol ether derivatives.
    Type: Application
    Filed: April 5, 2013
    Publication date: April 30, 2015
    Applicant: Merck Patent GmbH
    Inventors: Thomas Rudolph, Sylvia Eisenberg
  • Publication number: 20150119461
    Abstract: The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR? modulation such as diabetes.
    Type: Application
    Filed: January 9, 2015
    Publication date: April 30, 2015
    Inventors: Veera KONDA, Jan URBAN, Anuradha DESAI, Clinton J. DAHLBERG, Brian J. CARROLL
  • Patent number: 9018256
    Abstract: A feed additive includes at least one of p-thymol, a salt derivative and an ester derivative thereof for animals.
    Type: Grant
    Filed: September 2, 2013
    Date of Patent: April 28, 2015
    Assignee: Guangzhou Insighter Biotechnology Co., Ltd.
    Inventors: Xianfeng Peng, Zonghua Tan
  • Patent number: 9012503
    Abstract: Disclosed is an ophthalmic composition containing (A) not less than 50,000 units/100 mL of vitamin A, (B) not less than 0.4 W/V % of a polyoxyethylene polyoxypropylene glycol, and (C) trometamol.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: April 21, 2015
    Assignee: Lion Corporation
    Inventors: Nobuhito Tabuchi, Chieko Inoue, Manabu Hattori, Miyuki Miyake, Hazuki Tsutsui
  • Publication number: 20150105349
    Abstract: Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This (R)-1,2-propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agents cooling activity from inhibition when in the presence of a short-chain alcohol such as ethanol.
    Type: Application
    Filed: August 19, 2013
    Publication date: April 16, 2015
    Inventor: Edward T. Wei
  • Publication number: 20150099765
    Abstract: Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Inventors: Michael L. Hendrickson, Jeffrey C. Ockuly, Trevor M. Twose, Melinda L. Verdone, Brent D. Abraham, Richard R. Copp, James G. Farnham, Seth A. Hanson
  • Patent number: 9000035
    Abstract: The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g, a MetAP-2 inhibitor.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: April 7, 2015
    Assignee: Zafgen, Inc.
    Inventor: Thomas E. Hughes
  • Patent number: 8993623
    Abstract: The present invention relates to a method of lowering cholesterol in a patient in need thereof by administering to said patient a therapeutic effective amount of a compound selected from the group of Dihydroxyacetone phosphate (DHAP); 1-acyl-DHAP; 1-alkyl-DHAP; 1-alkyl-glyceraldehyde-3-phosphate (G3P); 1-alkyl, 2-acyl-G3P; 1-alkyl, 2-acyl-glycerol; 1-alkyl,2-acyl-glycerylphosphatidylethanolamine (GPE), 1-alkyl, diacyl glycerol (sn-1=16:0, sn-2=docosohexaenoic acid (DHA); sn-3=DHA) (sn-1 position has an alkyl ether bond, sn-2 and sn-3 positions have acyl bonds); 1-alkyl diacyl glycerol (sn-1=16:0, sn-2=18:1, sn-3=18:1) (sn-1 position has an alkyl ether bond, sn-2 and sn-3 positions have acyl bonds); triacyl glycerol (sn-1=16:0, sn-2=DHA, sn-3=DHA) (all three positions have acyl bonds); and triacyl glycerol (sn-1=16:0, sn-2=18:1, sn-3=18:1) (all three positions have acyl bonds) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: March 31, 2015
    Assignee: Phenomenome Discoveries Inc.
    Inventor: Dayan Burke Goodenowe
  • Publication number: 20150087621
    Abstract: Embodiments are directed to JAK kinase inhibiting prodrug compounds of Formula Ib, containing a promoiety that results in alcohol derivative of the parent compound upon removal and methods of using an effective amount of said prodrug compounds in the treatment of a JAK-mediated disease or disorder in a subject. Preferred promoieties include phosphate, phosphonate, phosphate salt, sulfate, or sulfate salt.
    Type: Application
    Filed: March 26, 2013
    Publication date: March 26, 2015
    Inventors: Federica Pericle, Jeremy A. Ross